Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy

British Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2010, Pages 268-272

  Paré, Laia ^a   Paez, David ^a   Salazar, Juliana ^b   Del Rio, Elisabeth ^a   Tizzano, Eduardo ^a   Marcuello, Eugenio ^a   Baiget, Montserrat ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

5 FU; Dihydropyrimidine dehydrogenase gene; Multiplex ligation dependent probe amplification (MLPA)

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DPYD GENE; FEMALE; GENE; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COHORT STUDIES; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); DNA MUTATIONAL ANALYSIS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; YOUNG ADULT;

EID: 77954470164     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03683.x     Document Type: Article

References (22)

1. Mazhar D, Stebbing J, Heller W. Recent advances in the systemic management of colorectal cancer. Future Oncol 2006 2 : 643 650.
2. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987 47 : 2203 2206.
3. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998 16 : 3537 3541.
4. Van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004 40 : 939 950.
5. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999 79 : 627 630.
6. Blasco H, Boisdron-Celle M, Ougnoux P, Calais G, Tournamille JF, Ciccolini J, Autret-Leca E, Le Guellec Ch. A well-tolerated 5-FU based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patients. Br J Clin Pharmacol 2008 65 : 966 970.
7. Yokota H, Fernandez-Salguero, P, Furuya, H, Lin, K, McBride, OW, Podschun, B, Schnackerz, KD, Gonzalez, FJ. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, and enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria. J Biol Chem 1994 269 : 23192 23196.
8. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res 1997 57 : 1660 1663.
9. Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, De Abreu RA, Smeitink JAM, Kayserili H, Apak MY, Christensen E, Holopainen I, Pulkki K, Riva D, Botteon G, Holme E, Tulinius M, Kleijer WJ, Beemer FA, Duran M, Niezen-Koning KE, Smit GPA, Jakobs C, Smit LME, Moog U, Spaapen LJM, Van Gennip AH. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999 104 : 1 9.
10. Raida M, Schwabe W, Häusler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, Höffken K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001 7 : 2832 2839.
11. Van Kuilenburg AB, Meinsa R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14+1 G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002 12 : 555 558.
12. Hormozian F, Schmitt J, Sagulenko E, Schwab M, Savelyeva L. FRA1E common fragile site breaks map within a 370 kilobase pair region and disrupts the dihydropyrimidine dehydrogenase gene (DPYD). Cancer Lett 2007 246 : 82 91.
13. den Dunnen JT, White SJ. MLPA and MAPH: sensitive detection of deletions and duplications. Curr Protoc Hum Genet 2006 Chapter 7: Unit 7.14.
14. Pare L, Marcuello E, Altes A, del Rio E, Sedano L, Salazar J, Cortes A, Barnadas A, Baiget M. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008 99 : 1050 1055.
15. Marcuello E, Altes A, Menoyo A, del Rio E, Gomez M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004 91 : 678 682.
16. Miller SA, Dyles DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988 16 : 1215.
17. MRC-Holland. SALSA MLPA kit P103 DPYD. Available at http://www.mlpa.com/ WebForms/WebFormProductDetails.aspx?Tag=tz2fAPIAupKyMjaDF\E\t9bmuxqlhe/ Lgqfk8Hkjuss|&ProductOID=56GZQQnogAM|).
18. EuroGentest. Available at http://www.eurogentest.org/web/files/public/ unit5/trials/MLPA-validation-summary.pdf).
19. van Kuilenburg AB, Meijer J, Mul AN, Hennekam RC, Hoovers JM, de Die-Smulders CE, Weber P, Mori AC, Bierau J, Fowler B, Macke K, Sass JO, Meinsma R, Hennermann JB, Miny P, Zoetekouw L, Vijzelaar R, Nicolai J, Ylstra B, Rubio-Gozalbo ME. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3). Hum Genet 2009 125 : 581 590.
20. Ticha I, Kleiblova P, Fidlerova J, Novotny J, Pohlreich P, Kleibl Z. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity. Cancer Chemother Pharmacol 2009 64 : 615 618.
21. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M, German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008 26 : 2131 2138.
22. Magne N, Etienne-Grimaldi MC, Cals L, Renee N, Formento JL, Francoual M, Milano G. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 2007 64 : 237 240.